Pain Syndromes In Patients With Lung Cancer
Peripheral Nerve Injections
Ultrasound For Msk Pain In Lung Cancer
Welcome Note
Role Of Surgery In Brain Metastasis
Role Of Radiation In Brain Metastasis
Welcome & Introduction
LD SCLC- Radiation
LD SCLC- Concurrent Chemotherapy
Treatment Decision In Brain Mets
Post Op Cavity Srs/Fsrs
Plan Evaluation-Srs/Fsrs.
AI & Radiomics in Lung Cancer Including SBRT
Proton Therapy & Lung SBRT
MR Guided Lung Sbrt
Simulation Including Motion Management
Contouring- Primary + Oar
Dose Prescription
Welcome & Introduction
Stratification & Prognosis of NSCLC Using Next-Generation Sequencing (NGS)
Why Liquid Biopsy Is Important In Clinical Routine...
Comprehensive NGS Testing & it’s Data Analysis In Oncology- TMH Experience
PET CT And CT Chest Features: When To Chase For Lung Malignancy
Endobronchial Obstruction In Thoracic Malignancy
Malignant PE: Where Are We Now?
Overview Of Fertility Preservation · Concept Of Oncofertility · Fertility Preservation Strategies
Fertility Preservation Strategies
Panel Discussion
Welcome & Introduction
Chemotherapy In Locally Advanced Lung CA- NACT / Adjuvant
Surgery After NACT In Locally Advanced Lung CA
Radiation In LALC
Maintenance Therapy In Locally Advanced Stage III NSCLC - Durvalumab
Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant
Debate: Systemic Therapy Sequencing In Early Stage Resectable Lung Cancer Neo Adjuvant Vs Adjuvant
Interpretation Of NGS What A Clinitian Should Know
Interpretation Of MET Amplification On EXON 14 Skip Mutation In NSCLC
Selection Of 1st Line Therapy For MET Amplification And MET EXON 14 Mutation In NSLC
Mechanism Of Resistance To MET TKI And Therapy Post Resistance IN NSCLC
Interpretation Of ROS 1 Rearrangement In NSCLC
Selection Of 1st Line Therapy For ROS 1 Rearrangement IN NSCLC
Mechanism Of Resistance To ROS 1and Therapy Post Resistance In NSCLC
Case Based Discussion: Optimal Sequencing of ALK Inhibitors in ALK+ NSCLC
Capmatinib: The Unmet Need In MET Ex14 Skipping Mutated NSCLC
wALK The Frontline in ALK NSCLC
Cyramza Clinical Evidence In Second Line Lung Cancer
Closing Remarks
Lung Cancer Treatment : Third Dimension
Immunotherapy For Lung Cancer: Whats New?
Immunotherapy: A Word Of Caution For The Pulmonologist
Welcome & Introduction
Chemotherapy, Targeted Therapy And Immunotherapy: How To Access Response?
AI In Lung Cancer
Image-Guided Tissue Sampling
Lung Cancer Screening Programs In India- Where Do We Stand?
Imaging Spectrum Of Lung Cancer
Anatomical Staging Of NSCLC On CT Scan
Performance Of Geriatric Assessments In India - Adaptation To Our Scenario
Intrinsic Capacity In Older Patients With Cancer
Comparing And Contrasting Psychological Assessments And Social Support In Older Patients In The West And Lmics
Welcome & Introduction
Screening & Prevention For Lung CA
Preop Evaluation For Surgical Fitness Of Surgery In Early Stage Lung Cancer
Evaluation Of Early Stage Lung Cancer - Role Of PET Scan
Surgery - Early Stage Lung Cancer
SBRT- Early Stage Lung Cancer
Early Stage Lung Cancer - Adjuvant Chemotherapy
Adjuvant Targeted Therapy In EGFR Mutated Early Stage Lung Cancer
Follow Up After Treatment Completion In Early Stage Lung Cancer
Case Based Viva- 15 Min - History/Physical Examination 15 Min- Investigations 30 Min- Selection Of Treatment & Follow Up
Interpretation Of PD1 1 MSI TMB In NSCLC
Selection Of 1st Line Immunotherapy Pdl1 > 50% & 1% In NSCLC
Selection Of 1st Line Immunotherapy In PDL1 Negative & Non Driver Mutations
Biomarkers For Predicting Efficacy Of IO (Non PDL1 NON MSI NON TMB)
Use Of Immunotherapy In Patients With Poor Performance Status
Redefining Survival Expectations in NSCLC_Keynote_189_and_Keynote_407
Radiotherapy In Lung Cancer- Where Are We?
Hot & Cold Ablative Procedures- Interventional Radiology
More Targets, More Drugs & More Choices- Medical Oncology
Choosing Right VAD In Lung Cancer Patients
Closing Remarks Followed By Dinner
Review Of The Best Thoracic Case
Welcome & Introduction